Enlivex (ENLV)
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a ce...
- Open
- 1.150
- High
- 1.160
- Low
- 1.020
- Prev. Close
- 1.160
- Volume
- 252.14K
- Turnover
- 274.20K
- Avg Price
- 1.087
- Bid/Ask Ratio
- --
- Amplitude
- 12.07%
- 52wk High
- 27.150
- Volume Ratio
- 2.99
- Turnover Ratio
- 5.40%
Enlivex Analyst Rating
View moreForecast & Rating
Aug 3, 2026Price forecast
$80.007172.73%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Aug 21 at 09:06 PM
12 Health Care Stocks Moving In Friday's After-Market Session
- PUBT · Aug 11 at 08:22 PM
Enlivex menaikkan saldo utang menjadi USD 19,2 juta dalam amandemen pembiayaan dengan Lind Global Asset Management
- Quartr · Jul 30 at 04:16 PM
ENLV: Allocetra shows strong early results in osteoarthritis, with treasury gains from Rain poised to support future growth
- Tip Ranks · Jul 30 at 12:33 PM
Enlivex Highlights 622% Surge in Rain Protocol Trading Volume to $860 Million
- benzinga_article · Jul 28 at 05:06 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
